Spero TherapeuticsSPRO +0.46%55 Debt-to-Equity is 0.05 as of Mar. 2026, which is 29% below its 10-year median of 0.07. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 963 Biotechnology companies, Spero Therapeutics ranks better than 71.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Spero Therapeutics's Debt-to-Equity or its related term are showing as below:
SPRO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.21
Current: 0.05
During the past 11 years, the highest Debt-to-Equity Ratio of Spero Therapeutics was 0.21. The lowest was 0.04. And the median was 0.07.
SPRO's Debt-to-Equity is ranked better than 71.96% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs SPRO: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Spero Therapeutics Debt-to-Equity Related Terms
Spero Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRO vs VXRT, ADCT, GNLX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Spero Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spero Therapeutics and its competitors. This is 29% below median its historical median of 0.07. Over the past decade, Spero Therapeutics' Debt-to-Equity has ranged from 0.04 to 0.21. According to the industry distribution chart, Spero Therapeutics ranks #270 out of 963 companies in the Biotechnology industry, placing it in the top 28%.
Is Spero Therapeutics' Debt-to-Equity too high?
Spero Therapeutics' current Debt-to-Equity of 0.05 is 29% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.21. The Biotechnology industry median Debt-to-Equity is 0.16. Spero Therapeutics' value of 0.05 is 68.8% below this industry median. Based on the distribution chart, Spero Therapeutics ranks #270 out of 963 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Debt-to-Equity compare to VXRT and ADCT?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #270 out of 963 companies for Debt-to-Equity. This puts Spero Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Spero Therapeutics' value of 0.05 is 68.8% below this benchmark. Historically, Spero Therapeutics' own Debt-to-Equity has ranged from 0.04 to 0.21 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.16, Spero Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spero Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current Debt-to-Equity is 0.05, which is 29% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.18 — trading 107.6% above its estimated fair value. The current Debt-to-Equity is 0.05, which is 29% below median its 10-year median of 0.07 and 68.8% below the Biotechnology industry median of 0.16. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $2.18 is trading 107.6% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
Debt-to-Equity: 0.05 (29% below median its 10-year median of 0.07)
GF Value™: $1.05 vs. price of $2.18 (107.6% above fair value)
Industry Position: 68.8% below the Biotechnology median (#270 of 963)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score
Get the complete analysis for SPRO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
